Danny Brinkley is Head of Research at invoX Belgium NV, where he leads research activities spanning inhaled pharmaceuticals, biologics, device–drug combination products and advanced inhalation technologies. He has responsibility for the scientific leadership of multiple development programmes.
Danny holds a BSc (Hons) in Pharmaceutical Science from London Metropolitan University and has accumulated 29 years of experience in respiratory drug development and inhalation science. Prior to joining invoX, he held senior scientific and development roles at GSK, Novartis and Teva, contributing to the advancement of inhaled medicines and respiratory drug delivery technologies.
His primary research interests include inhalation drug delivery, soft mist inhaler technologies, aerosol characterisation, lung deposition modelling, inhaled biologics, and the development of complex drug–device combination products. He has extensive experience in translating innovative respiratory therapies from concept through development while integrating regulatory, pharmaceutical and device-engineering considerations.
Throughout his career, Danny has contributed to the development of numerous respiratory products and platform technologies, applying multidisciplinary expertise across formulation development, inhalation devices, aerosol performance testing and product development strategy to support the delivery of improved therapies for patients with respiratory disease
